FDA Approves Rusfertide for Polycythemia Vera

Published Date: 01 Sep 2026

Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.

Read Full News

Latest News

Black Canadians Face Multiple Barriers to Blood Donation

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Laser Therapy Shows Promise for Brain Tumors

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

Can Accelerated Salvage RT Improve Prostate Cancer Control?

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Ibrutinib Fails in High-Risk Early-Stage CLL

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

Sequencing Method Flags AML Relapse Risk Around Transplant

High-sensitivity tracking of a high-risk mutation may help identify risk for relapse in patients with acute myeloid leukemia around the time of allogeneic transplant.

Are Microplastics Feeding Cancer Risk?

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

Todays Updates

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

Todays Updates

Thymus Radiation Exposure Tied to Worse Lung Cancer Outcomes

The thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.

Latest News

Barriers to blood donations from Black people in Canada are rooted in racism and restrictive policies.

Researchers followed 787 patients with brain tumors treated with laser therapy for up to 5 years.

After biochemical recurrence, hypofractionated RT may be no more effective than standard RT for disease control — and may have more late side effects.

Ibrutinib improves event-free survival in certain genetic subgroups of early-stage chronic lymphocytic leukemia but fails to extend overall survival.

High-sensitivity tracking of a high-risk mutation may help identify risk for relapse in patients with acute myeloid leukemia around the time of allogeneic transplant.

Microplastics are everywhere, in the environment and the human body. But as public concern about possible health effects grows, evidence of a cancer connection remains thin.

News All Time

Transgender Individuals Prefer HPV Self-Swabs

Transgender and gender-diverse individuals prefer self-collected HPV testing for cervical cancer screening, a new survey shows.

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control

For men with intermediate-risk prostate cancer, SBRT may beat longer-course radiotherapy in some measures of quality of life, but not disease-free survival.

FDA Approves Iberdomide Combo for Multiple Myeloma

Outcomes improve when a novel, first-in-class immunomodulatory drug is combined with daratumumab and dexamethasone in previously treated patients.

Can Electronic PRO Monitoring Ease Fatigue in Breast Cancer?

Weekly electronic symptom monitoring was associated with improved fatigue and physical functioning in a randomized trial of patients with metastatic breast cancer.

Wide Variation Seen in Lung Screening False-Positive Rates

US radiologists vary substantially in their reading of low-dose CT lung cancer screens, highlighting a need for measures to help standardize interpretation.

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

A new real-world analysis helps clarify the most informative prognostic PSA benchmark in men with metastatic castration-sensitive prostate cancer.

Do High-Risk Features of Prostate Cancer Boost HT Benefit?

Researchers analyze individual patient data from five randomized phase 3 trials comparing PORT alone vs PORT plus hormone therapy in patients with recurrent prostate cancer.

AVD Chemo Regimen Shows Promise in Older Patients With HL

Researchers compare first-line chemotherapy regimens in older patients with classical Hodgkin lymphoma to assess whether AVD is associated with better outcomes in routine care.

Tissue-Free ctDNA Strongly Prognostic of Recurrence in TNBC

Tissue-free ctDNA may be comparable to tumor-informed assays in detecting molecular residual disease.

Enzalutamide vs Abiraterone: Which is Better for mCSPC?

Researchers compare enzalutamide vs abiraterone in the metastatic castration-sensitive prostate cancer setting.

Inconclusive BRCA Results Linked to Higher BC Risk

A new study assesses breast and ovarian cancer risk in women who carry a BRCA variant of uncertain significance or have a noninformative negative result.

OA Tied to Arthritis AE Risk in ICI-Treated Patients

In patients with cancer receiving immune checkpoint inhibitor therapy, osteoarthritis is linked to the risk for inflammatory arthritis immune-related adverse events.

Stem Cell Transplant Linked to Longer Survival in CMML

Researchers evaluate the impact of allogeneic stem cell transplantation in chronic myelomonocytic leukemia across BLAST and BLAST-Mol clinical risk models.

Jazz Seeks Second-Line Lurbinectedin SCLC Withdrawal

The planned label change follows failure of lurbinectedin to improve overall survival in the phase 3 postmarketing trial; the first-line maintenance indication remains unaffected.

Gatekeeping May Reduce Pediatric Cancer Trial Participation

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

AI Framework Helps Classify Renal Tumors, Predict Outcomes

A deep learning system trained on whole-slide images classifies nine renal tumor subtypes with high accuracy and outperforms traditional grading in predicting patient outcomes.

Recommended News For You

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

Stevia leaf extract has potential as anticancer treatment, researchers find

LAIs vs Oral Antipsychotics for Bipolar I Rehospitalization

Breast cancer-related fatigue: The benefits of adapted physical activity

The Truth About Apple AirPods

Testosterone recovery linked to overall survival in high-risk prostate cancer

Novel biomarker has potential for predicting and treating skin cancer metastasis

Recommended Articles For You

The Genetics of Bernard Soulier Syndrome: What We Know so Far 

Amivantamab Plus Chemotherapy Outperforms Standard Care in Post-Osimertinib NSCLC 

Transfusing the Future: Exploring the Possibilities of Blood Transfusions 

A Review on Genetic Predispositions and Clinical Advancements of Multiple Myeloma Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Talquetamab Combos Show Survival Benefit in r/r Myeloma

2.

From sweetener to cancer fighter? Fermented stevia shows promise in pancreatic cancer study

3.

Year in Review: Non-Small Cell Lung Cancer

4.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

5.

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

1.

Targeted Therapies for Breast Cancer: What’s New?

2.

Ultrasound: A Promising Tool in the Fight Against Malignant Breast Cancer

3.

Adjuvant Atezolizumab in TNBC: What Recent Trials Reveal About Its Role

4.

Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology

5.

Sorafenib: Understanding the science behind a powerful cancer drug 

1.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

Asian Symposium on Advancement in Hematology and Oncology

1.

An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion

2.

ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part III

4.

Common Cancer Myths Debunked

5.

Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot